Our pipeline

This is our journey towards a future market authorization and making our drug products available for patients world-wide.

Product & indication
Pre-clinical
Phase Ib / IIa
Phase IIb / III
Phase III
LTX-109 nasal spray
A therapeutic against influenza and similar illnesses
  • Completed
  • Q1 2025 – Q3 2026
  • Q4 2026 – Q4 2027
  • Start Q4 2027
LTX-109 inhaled form
Inhaled formulation development and pre-clinical testing
  • 2025 – 2027
  • To be planned
  • To be planned
  • To be planned
LTX-109 nasal spray
A prophylactic against influenza and similar illnesses
  • Completed
  • To be planned
  • To be planned
  • To be planned
  • Completed
  • Ongoing

Do you want to be part of our journey? See if there are available positions under Careers.

Careers